The NHS will include an AI-powered triage tool in the NHS App in an attempt to cut waiting lists and improve care for ...

Roche's Genentech unit has forged an alliance with Astex, worth up to $515 million, to partner on a fragment-based drug ...

Novartis has reached a deal to buy Myricx Bio for up to $1.5 billion, giving it control of the London, UK, start-up's ...

Sir Chris Hoy has said he feels "very proud" when he hears of people taking part in the charity cycling event he set up last ...

UK psychedelic medicines developer Beckley Psytech is preparing to take its psychedelic medicine for severe depression into a pivotal trials programme on the back of a positive phase 2b readout. The ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU. The EMA's human medicines ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

The social media landscape is shifting. As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin is rapidly gaining traction. A year on from its ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

Bill Gates has made a $50 million donation to the Dementia Discovery Fund, a collaboration between pharma, the UK government and the charity Alzheimer’s Research UK, that aims to challenge the ...

A cannabis-derived drug developed by Germany's Vertanical has shown efficacy in phase 3 as a treatment for chronic pain, offering the prospect of an alternative to opioid drugs that carry the risk of ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations. The Danish ...